Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ELCC 2018 | Treating NSCLC with CNS involvement: TKIs with high penetrance

The treatment of brain metastases in non-small cell lung cancer (NSCLC) is a challenge, as the majority of the drugs used to treat NSCLC exhibit low penetrance to the brain. Here, Marina Garassino, MD, of the Istituto Nazionale dei Tumori, Milan, Italy, discusses the next-generation EGFR and ALK inhibitors that can be used in cases of CNS involvement. This video was recorded at the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland.